MINNEAPOLIS, July 14 /PRNewswire-FirstCall/ — Biotel Inc. (OTC Bulletin Board: BTEL) today announced that CardioNet has advised Biotel that it is terminating the Merger Agreement with Biotel due to a failure of Biotel to comply with the terms of the agreement. Biotel believes it has complied with all terms of the agreement and that CardioNet’s claim is without merit and inconsistent with CardioNet’s representations to Biotel. Biotel is considering its legal options.
Biotel President and CEO Steve Springrose said: “It is unfortunate that CardioNet took this action. Biotel has developed significant new products in wireless MCT and event recorder applications. These products are of significant value to arrhythmia service organizations, and Biotel believes these products are cost effective and well positioned for the current medical reimbursement climate. Biotel has worked to build its shareholder value by expanding its range of products and services. Biotel will continue to position these new wireless products to maximize growth and opportunities going forward.”
Biotel supplies completed medical devices and clinical research services to medical companies including
ECG diagnostic products
wireless MCT and event recorders, Holter recorders,
tissue management devices, and
24/7 clinical ECG research services
SOURCE Biotel Inc.